FDA Approves Abbott's SimpleScreen CRC, Triggering $100M Milestone
ABT sits 29% above its 52-week low of $81.97.
Summary
Abbott won FDA approval for SimpleScreen CRC, a colorectal cancer screening test for average-risk adults 45+. The approval aligns with Medicare and ACS guidelines, likely expanding clinical access. It also triggers a $100M milestone payment to Freenome under their contract. This follows Abbott's Q2 beat and raised guidance, adding a new growth driver in diagnostics. The approval strengthens Abbott's position in cancer screening, a market with significant potential.
At the time of this announcement, ABT was trading at $106.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $182.9B. The 52-week trading range was $81.97 to $137.49. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.